

---

## News Release

For Immediate Release

21 August 2013

Contact: **Tricia Thompson**  
Business Development  
+1 (610) 539-3670

### USA Phase II Clinical Trial Begins for PluroGen's PluroGel® PN

(Norristown, Pennsylvania, USA, 21 August 2013) - PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that its PluroGel® PN topical antibiotic, utilizing a unique combination of antibiotics in its differentiated and patent protected PluroGel®, has started its USA Phase II clinical trial for infected diabetic foot ulcers.

Currently, PluroGen's research shows that there is no topical antibiotic approved by FDA for the treatment of infections of diabetic foot ulcers. Diabetes is a disease estimated to afflict approximately 28 million people in the US alone. Many diabetics have the additional problem of a chronic condition known as diabetic foot ulcer and patients with diabetic foot ulcer experience a high rate of infection known as diabetic foot infection. Currently, it is thought that approximately 3 million patients per year are treated for diabetic foot infection in the USA. The worldwide market for diabetic foot infection is estimated at approximately \$1.5 billion in 2011 with the affliction and market expected to continue growth, driven by the aging population, growing obesity and the increasing diagnosis of diabetes.

"We have achieved another major milestone this summer." said Neal Koller, President and CEO of PluroGen. "Beginning the Phase II clinical trial builds on the success of the approximately 12,000 patients treated with the early version of PluroGel® PN at the University of Virginia which supported FDA's agreement to fast-track our clinical trial plan. The Phase II clinical trial is a big step towards entrance into the USA market, to improve care for patients and to increase shareholder value."

#### About PluroGen Therapeutics, Inc.

PluroGen Therapeutics, Inc. is a burn, wound, and skin care company providing clinically advanced and superior products from its multiple, patent-protected technology platforms. The Company's primary platform is its core PluroGel® surfactant technology which provides products with paradigm-shifting, superior and differentiated Core, Bio-Physical, and Performance Functions resulting in unique and advantaged Multi-Function products. Products based on PluroGel® are University developed and are in routine use, having shown superior results on more than 12,000 patients in two different patient populations- severe burns and non-healing wounds. PluroGen's three technology platforms are configured to deliver a variety of medicinal and beneficial compounds covering the six key areas of treatment in tissue management and healing: 1. Cleansing; 2. Anti-Infection; 3. Reduced Pain; 4. Anti-Inflammation; 5. Tissue salvage; 6. Tissue regeneration. PluroGen has a strong new product pipeline and its senior management, operations team, boards and principal investigators are all recognized global, commercial and clinical leaders in PluroGen's target markets of burn and wound care.

More information can be found on the company web site at [www.plurogen.com](http://www.plurogen.com). For PluroGen Investor Information please call +1 (610) 539-3670.

#### Safe Harbor Statement:

The statements in the press release that relate to PluroGen's (the company) expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.